Post-Transplant Complications.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Hematopoietic cell transplantation (HCT) offers curative potential for high-risk conditions.
• Post-transplant complications, including graft dysfunction and non-infectious pulmonary complications (NIPCs), present significant challenges.
• Current treatment options for many HCT complications are suboptimal.

Purpose of the Study:

• To review the diverse complications following allogeneic HCT (allo-HCT).
• To highlight the challenges in diagnosing and treating conditions like poor graft function (PGF) and NIPCs.
• To discuss advancements in managing severe complications such as transplant-associated thrombotic microangiopathy (TA-TMA).

Main Methods:

• Review of existing literature on post-allogeneic HCT complications.
• Analysis of the pathophysiology and clinical presentation of PGF, NIPCs, and TA-TMA.
• Evaluation of current and emerging therapeutic strategies, including novel agents and complement inhibitors.

Main Results:

• Poor graft function affects 5-30% of patients, lacking standardized treatment guidelines.
• Non-infectious pulmonary complications (NIPCs) have ill-defined pathophysiology and high mortality (e.g., >50% for idiopathic pneumonia syndrome).
• Complement inhibitors have improved outcomes for transplant-associated thrombotic microangiopathy (TA-TMA), previously a lethal complication.

Conclusions:

• Allogeneic HCT is associated with a spectrum of severe complications requiring better management strategies.
• Further research is needed to define and standardize treatments for PGF and NIPCs.
• Targeted therapies, such as complement inhibitors for TA-TMA, demonstrate the potential for improved post-transplant care.